A key U.S. government trial of Gilead Sciences Inc’s experimental coronavirus treatment may yield results as early as mid-May, according to the study’s lead investigator, after doctors clamored to enroll their patients in the study.
After a tepid start to the year, investment bankers, hedge-fund employees and asset-management professionals are now poised to see higher year-end incentive...